Glucagon-like peptide-1 receptor agonists (GLP-1R) are employed in the treatment of type 2 diabetes [18,19] but have recently been of interest in their potential to modify the progression of a range of neurological disorders [20,21] including PD [22,23]. This evidence concerns the gene GLP1R and nervous system disorder.